Medical Director, Oncology (Genitourinary Focus)

The Medical Director, Genitourinary Oncology is a critical leadership role responsible for advancing clinical development, shaping medical strategy, contributing to foundational clinical evidence generation, and engaging external stakeholders in support of Natera’s molecular diagnostics in GU cancers (e.g., prostate, bladder, kidney, and other genitourinary malignancies). This individual, under the oversight of a Senior Medical Director, will contribute to an evolving understanding of cancer biology while driving the adoption of transformational diagnostics into routine clinical practice.

This role is ideal for a radiation oncologist with specialized expertise and interest in GU cancers who is excited to translate cutting-edge molecular diagnostics into clinical practice and shape the future of precision oncology at scale.

Primary Responsibilities:

Partner with the Senior Medical Director, Genitourinary Oncology to develop and execute clinical strategies supporting Natera’s molecular diagnostic tools for GU cancers, including minimal residual disease (MRD) and ctDNA-based monitoring.

Lead the design and implementation of clinical studies and treatment protocols that integrate Natera’s technology into standard GU oncology care.

Recruit and engage leading principal investigators (PIs) and clinical sites in GU oncology to participate in company-sponsored studies; manage study timelines and budgets in collaboration with Clinical Trial Operations.

Advise on product development for the GU oncology portfolio, identifying clinical unmet needs, new product opportunities, key product features, intended use, test report content, and minimum validation requirements.

Provide post-launch medical affairs support, including interpretation of test results, clinical consultation for healthcare providers, and guidance on patient counseling (pre- and post-test).

Serve as GU oncology expert for support of high-value engagement and events identified by Strategic Accounts, Area Sales and Marketing leaders, commercial or clinical leadership.

Lead medical education initiatives, including external training, launch planning, and the creation of scientific and clinical materials specific to GU malignancies.

Identify and recruit Key Opinion Leaders (KOLs) in GU oncology to serve on advisory boards and contribute to strategic planning.

Support the publication strategy by collaborating with Scientific Communications on manuscripts, abstracts, and conference presentations in GU oncology.

Contribute to regulatory strategy by providing medical input into submissions related to GU cancer diagnostic products.

Represent Natera’s medical voice externally through public relations, industry panels, advisory boards, and medical conferences, with a focus on GU oncology.

Qualifications:

M.D. required (board-certified or board-eligible in Radiation Oncology preferred)

Residency training in Radiation Oncology

At least 3 years of post-residency clinical experience in GU cancers (prostate, bladder, kidney, etc.) as a primary treating radiation oncologist

Deep knowledge of treatment paradigms, clinical guidelines, and diagnostic workflows in GU cancers

Minimum 3 years of clinical trial experience in academic, biotech, or pharmaceutical settings

Willingness to travel 40% (primarily U.S.-based, with occasional international travel)

Knowledge, Skills, and Abilities:

Expertise in clinical trial design, regulatory/compliance frameworks, and biostatistics

Strong understanding of evolving treatment landscapes in GU cancers (including targeted therapies, immunotherapy, and biomarker-driven approaches)